Clarity Pharmaceuticals (CU6.AX) Earnings Analysis

Clarity Pharmaceuticals (CU6.AX) next reports earnings on 2026-08-26, consensus EPS -0.14579 AUD. Last quarter (2026-02-25) it missed with EPS -0.153 AUD vs -0.0826 AUD est (-85.2%). It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E -9.14.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CU6.AX next report earnings?

Next earnings date2026-08-26
Consensus EPS estimate-0.14579 AUD
Revenue estimate0.01B

CU6.AX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-25-0.153 AUD-0.0826 AUD-85.2%Miss
2025-02-28-0.07435 AUD-0.0735 AUD-1.2%Miss
2024-08-23-0.08834 AUD-0.04 AUD-120.8%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

CU6.AX valuation and analyst view

Trailing P/E-9.14
Trailing EPS-0.26457 AUD
Price / book4.00
Dividend yield0.00%
Market cap0.87B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Clarity Pharmaceuticals (CU6.AX)'s next earnings date?

Clarity Pharmaceuticals is next scheduled to report on 2026-08-26, with a consensus EPS estimate of -0.14579 AUD and revenue estimate of 0.01B.

Did CU6.AX beat earnings last quarter?

In its 2026-02-25 report, CU6.AX posted EPS of -0.153 AUD versus a -0.0826 AUD estimate — a miss of 85.2%.

What is CU6.AX's earnings track record?

Over the last 3 reported quarters with consensus data, CU6.AX beat estimates 0 times (0%).

What is CU6.AX's current P/E ratio and EPS?

CU6.AX trades at a trailing P/E of -9.14 on trailing EPS of -0.2645724958491814 AUD.

What do analysts rate CU6.AX?

CU6.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.